New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:03 EDTONXX, BAYRYBayer and Onyx Pharmaceuticals say sorafenib trial did not meet primary endpoint
Bayer (BAYRY) and Onyx Pharmaceuticals (ONXX) said a Phase III Trial of sorafenib, an adjuvant therapy for a form of liver cancer, did not meet primary endpoint. "We are disappointed that the trial did not meet its primary endpoint. However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer," said the Bayer HealthCare Executive Committee.
News For BAYRY;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
05:25 EDTBAYRYRegeneron reports approval of Eylea by Japan
Subscribe for More Information
June 25, 2015
14:01 EDTBAYRYBayer initiated with a Buy at HSBC
Subscribe for More Information
08:00 EDTBAYRYBayer to hold a meeting
Subscribe for More Information
June 23, 2015
10:31 EDTBAYRYMonsanto says Bayer crop chemicals unit an option, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use